心血管

订阅

MedSci主页 / 所有栏目 / 心血管

FDA批准新型胆固醇药物（PCSK9抑制剂）

2015-07-27 MedSci MedSci原创

胆固醇新药低密度脂蛋白
关注

美国FDA近日批准了新型降胆固醇药物。赛诺菲公司的Praulent (alirocumab)获得了FDA的批准，此外安进公司的Repatha(evolocumab)将在8月27日得到FDA的最终决议。这两种注射用药物都是PCSK9抑制剂，而且FDA为这两种药物开了绿灯。这两种药物都是用于降低低密度脂蛋白（通常被称作坏的LDL胆固醇）。通过抑制PCSK9，调节机体的胆固醇水平。现在用于治疗高胆固醇的

美国FDA近日批准了新型降胆固醇药物。赛诺菲公司的Praulent (alirocumab)获得了FDA的批准，此外安进公司的Repatha(evolocumab)将在8月27日得到FDA的最终决议。这两种注射用药物都是PCSK9抑制剂，而且FDA为这两种药物开了绿灯。


这两种药物都是用于降低低密度脂蛋白（通常被称作坏的LDL胆固醇）。通过抑制PCSK9，调节机体的胆固醇水平。现在用于治疗高胆固醇的药物主要是他汀类药物。

他汀类药物与PCSK9抑制剂的作用机理不同。他汀类药物可以组织肝脏的LDL胆固醇的产生。高胆固醇会导致动脉处形成斑块，这直接导致了心脏病、堵塞和卒中。临床试验表明Praulent无论是单独使用还是联用他汀类药物，可以降低46-64%的胆固醇。每两周或者四周注射一次，而且完全可以在家里进行注射给药。FDA同时也说明了这种药物对于那些最难治疗的病人是一种选择。

美国心脏协会（AHA）在2013年的时候修订了其科学指南。AHA不再强调具体的LDL靶点的背景，推荐所用处于风险中的患者使用他汀类药物。现在由于有可能出现LDL的超低水平，考虑到PCSK9抑制剂的研发，所以仍不清楚是否会很快再次改写指南。医药数据分析公司GlobalData预测这两种药物上市后到2023年在美国以及欧洲、日本和中国的销售额将达到167亿美元。但是，这种药物对于PCSK9突变的人群并不能起作用。这些人LDL水平较低，不易患心脏疾病。

原始出处：

FDA approves new cholesterol drug.blog.heart.org.July 24,2015

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-08-16 wjywjy

    #PCSK9抑制#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-11-20 bugit

    #FDA批准#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2016-06-17 FukaiBao

    #Csk#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2016-03-15 Tamikia

    #PCS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-11-16 jklm09

    #抑制剂#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-07-29 bearing

    前蛋白转化酶枯草溶菌素9

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1786845, encodeId=f5ba1e8684584, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 16 21:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839381, encodeId=3675183938118, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Nov 20 18:00:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777235, encodeId=8ce91e7723595, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Jun 17 17:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Mar 15 04:00:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851260, encodeId=7af51851260c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 16 14:00:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35117, encodeId=74083511e21, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:13:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33800, encodeId=bc1233800e2, content=前蛋白转化酶枯草溶菌素9, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acdd1632351, createdName=bearing, createdTime=Wed Jul 29 17:17:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33631, encodeId=61b53363166, content=我想知道中文名叫什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Tue Jul 28 08:47:00 CST 2015, time=2015-07-28, status=1, ipAttribution=)]
    2015-07-28 Messichen1992

    我想知道中文名叫什么

    0

相关资讯

取消脂肪和胆固醇的摄入限制意味着什么？

最近发表于美国医学会杂志（JAMA）上的一篇文章中，来自塔夫茨大学弗里德曼营养科学与政策学院的Dariush Mozaffarian教授和来自波士顿儿童医院的David Ludwig教授讨论了最新发布的《美国居民膳食指南》中的一个新推荐：取消总脂肪摄入量占比的限制。Mozaffarian教授认为对于总脂肪摄入量的限制是没有根据的，而且这会对行业和消费者产生误导。当膳食指南推荐低脂饮食时，低脂和不含

Nutrients：鸡蛋胆固醇不可怕，降低炎症也有它

糖尿病患者早餐吃一个鸡蛋和吃一碗燕麦粥是一样健康的？甚至鸡蛋更健康？College of Agriculture, Health, and Natural Resources的营养学教授Maria-Luz Fernandez的最新研究成果表示鸡蛋可能对糖尿病患者属于更健康的饮食。Fernandez教授和她的同事们得到的证据表明，一个鸡蛋可能不仅属于糖尿病患者饮食中可以接受的类别，它可能会被证明提供

吃货们，平衡蛋白质和碳水化合物摄入，不用再节食！

研究显示，饮食控制限制卡路里摄入能够降低胆固醇、提高胰岛素敏感度，甚至延长哺乳动物寿命。现在新的研究表明，至少在小鼠中，低蛋白质、高碳水化合物的饮食方式能与限制卡路里有相似的效果。“两者相比，低蛋白高碳水化合物的饮食方式与减少40%的卡路里摄入效果相当”，本文的作者之一，来自悉尼大学的Stephen Simpson说道， “除了极少数狂热分子，没人能长时间保证减少40%卡路里摄入，而且这么做还会有

JACC：肠道胆固醇吸收率低的血透患者更能获益于阿托伐他汀治疗

瑞士伯尔尼大学Silbernagel G等人研究了血透患者中，肠道胆固醇的吸收率与阿托伐他汀治疗的收益率相关性，其研究成果发表在6月份Journal of the American College of Cardiology期刊上。 背景：血液透析患者肠道胆固醇的吸收高；相对于其他他汀治疗（抑制胆固醇合成）患者而言，其他汀受益率较低。 目的：本研究旨在探讨个体胆固醇的吸收率是否会影响阿托伐他汀

郭艺芳：降胆固醇治疗策略的新趋势

河北省人民医院 郭艺芳近日，有三则关于降胆固醇治疗的消息在各类媒体广泛传播：其一，IMPROVE-IT研究结果在新英格兰医学杂志正式发表；其二，选择性胆固醇吸收抑制剂临床应用中国专家共识正式发表；其三，FDA将就两种降胆固醇新药PCSK9抑制剂Alirocumab与Evolocumab举行专家听证会。综合分析这三则消息，可以看出降胆固醇的药物治疗策略正从他汀类药物一枝独秀的局面转变为以他汀为主、胆

衰！胆固醇过高了生不出孩子，胆固醇过低了性早熟，怎么破？

衰！胆固醇过高了生不出孩子，胆固醇过低了性早熟，怎么破？既往大多数关于胆固醇的研究集中在与心脏病及动脉堵塞之间的关系。然而，这种蜡状脂肪样的东西在细胞生长方面起着至关重要的关系，而且是类固醇和激素分泌必不可少的基础。近日，华盛顿大学医院的一项研究揭示了控制细胞内胆固醇转运的关键性分子是如何影响细胞分泌支持怀孕以及引发性早熟的类固醇激素的能力。研究人员表示他们的发现为探究不孕症以及性早熟（尤其是女性